Close Menu

PhRMA

Tell Me, Please

A US senator has sent letters to two biotech and pharmaceutical industry groups to ask about their approaches to handling sexual harassment, according to Stat News.

New membership rules by PhRMA governing R&D spending come as the industry tries to change its image as profiteers of sickness and disease. 

In an analysis of 10 drug companies, pharma consulting firm Diaceutics found that very few of them are prepared to break away from the traditional drug development model and launch personalized medicine products in the next decade.

John Castellani, CEO of the Pharmaceutical Research and Manufacturers of America, said that while the industry's commitment to using genomic strategies to advance targeted therapies is growing, the road ahead is fraught with scientific, regulatory, and reimbursement challenges.

A Supreme Court decision against drug developers in Sorrell v. IMS Health could potentially hamper how pharmacy benefit managers can use physician prescription data to drive adoption of pharmacogenomically guided products.

Industry observers have noted that the move from the outspoken Billy Tauzin, also known as the "Swamp Fox," to an insider business lobbyist-type like Castellani represents a shift in PhRMA's advocacy style. Where that leaves PhRMA's support for personalized medicine, a pet cause of Tauzin's, is hard to determine in the post-healthcare-reform climate in Washington.

Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.

A WHO panel is calling for a global registry of human germline gene-editing projects, according to Stat News.

Vox writes that lab mishaps involving pathogens are quite common.

In Genome Biology this week: analysis of wild and cultivated peach genomes, Hi-C-based pipeline for assembling microbial genomes from metagenomic data, and more.